Klin Farmakol Farm. 2010;24(3):135-137

Vascular disrupting (targeting) drugs

Jan Novotný
Onkologická klinika VFN a 1. LF UK, Praha
Institut onkologie a rehabilitace Na Pleši, s. r. o., Praha

In clinical practice, we have many products intervening on the level of blood vessel formation. It the so-called anti-angiogenic drugs.

In this article, we deal with drugs targeted against the blood vessels, vascular disrupting drugs (EAD). The aim of these drugs is to make

rapid destruction of existing blood vessels, causing a sharp drop in tumor perfusion and thus induce tumor necrosis. While many antiangiogenic

drug delivery has undergone clinical phase III study, and are routinely used drugs before the second group are at the very

beginning of clinical trials and only one of them advanced to the second phase of tests.

Keywords: angiogenesis, vadimezan, fosfretabulin, vascular disrupting agent

Published: October 15, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Novotný J. Vascular disrupting (targeting) drugs. Klin Farmakol Farm. 2010;24(3):135-137.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Siemann DW, Horsman MR. Vascular targeted therapies in oncology. Cell Tissue Res. 2009; 335: 241-248. Go to original source... Go to PubMed...
    2. Siemann DW, Chaplin DJ, Horsman MR. Vascular-targeting therapies for treatment of malignant disease. Cancer 2004; 100: 2491-2499. Go to original source... Go to PubMed...
    3. Strieth S, Eichhorn ME, Sauer B, Schulze B, Teifel M, Michaelis U, Dellian M. Neovascular targeting chemotherapy: Encapsulation of paclitaxel in cationic liposomes impairs functional tumor vasculature. Int J Cancer 2004; 110: 117-124. Go to original source... Go to PubMed...
    4. Baguley BC, Ching LM. DMXAA: an antivascular agent with multiple host responses. Int J Radiat Oncol Biol Phys 2002; 54: 1503-1511. Go to original source... Go to PubMed...
    5. Rustin GJ, Galbraith SM, Anderson H, Stratford M, Folkes LK, Sena L, Gumbrell L, Price PM. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 2003; 21: 2815-2822. Go to original source... Go to PubMed...
    6. Kanthou C, Tozer GM. Tumour targeting by microtubule-depolymerizing vascular disrupting agents. Expert Opin. Ther. Targets 2007; 11: 1443-1457. Go to original source... Go to PubMed...
    7. Chaplin DJ, Horsman MR, Siemann DW. Current development of small molecule disrupting agents. Curr. Opin Invest Drugs 2006; 7: 522-528.
    8. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005; 5: 423-435. Go to original source... Go to PubMed...
    9. Horsman MR, Siemann DW. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 2006; 66: 11520-11539. Go to original source... Go to PubMed...
    10. Rustin GJS, Bradley C, Galbraith S, Stratford M, Loadman P, Waller S, Bellenger K, Gumbrell L, Folkes L, Halbert G 5,6-dimethylxanthenone- 4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study. Br J Cancer 2003; 88: 1160-1167. Go to original source... Go to PubMed...
    11. Tolcher AW, Forero L, Celio P, Hammond LA, Patnaik A, Hill M, Verat-Follet C, Haacke M, Besenval M, Rowinsky EK. Phase I, pharmacokinetic, and DCE-MRI correlative study of AVE8062A, an antivascular combretastatin analogue, administered weekly for 3 weeks every 28 days. J Clin Oncol 2003; 22(Suppl): 208 (Abstract 834).
    12. Beerepoot LV, Radema SA, Witteveen EO, Thomas T, Wheeler C, Kempin S, Voest E. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol 2006; 24: 1491-1498. Go to original source... Go to PubMed...
    13. Hande KR, Hagey A, Berlin J, Cai Y, Meek K, Kobayashi H, Lockhart AC, Medina D, Sosman J, Gordon GB, Rothenberg ML. The pharmacokinetics and safety of ABT-751, a novel orally bioavailable sulfonamide antimitotic agent: results of a phase I study. Clin Cancer Res 2006; 9: 2834-2840. Go to original source... Go to PubMed...
    14. Ricart AD, Cooney M, Sarantopoulos J, Brell J, Locke KW, Gammans RE, Medina G, Zambito A, Tolcher W, Remick SC. A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of MN-029, a novel vascular disrupting agent (VDA), in patients with advanced solid tumors. J Clin Oncol 2006; 24 (Suppl): 144 (Abstract 3096). Go to original source...
    15. Greystoke A, Blagden S, Thomas AL, Scott E, Attard G, Molife R, Vidal L, Pacey S, Sarkar D, Jenner A, De-Bono JS, Steward W. A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours. Ann Oncol 2006; 8: 1309-1313. Go to original source... Go to PubMed...
    16. Mooney CJ, Nagaiah G, Fu P, et al. A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid 2009; 19: 233-240. Go to original source... Go to PubMed...
    17. Mita AC, Heist RS, Aren O, et al. Phase II study of docetaxel with or without plinabulin (NPI-2358) in patients with nonsmall cell lung cancer (NSCLC). J Clin Oncol 2010; 28(Suppl.): 7592. J Clin Oncol 2010; 28: 15(suppl; abstr 7592). Go to original source...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.